OXFORD, UK — Refeyn, the pioneer in mass photometry, has announced the launch of its new Samux^deputy mass photometer, which dramatically improves the time and cost-effectiveness of adeno-associated virus (AAV) characterization. Presented at PepTalk, the Samux^deputy overcomes the shortcomings of current gold standard analytical methods by allowing users to quickly and cost-effectively determine empty/full capsid ratios for AAVs of any serotype on the bench using very low sample volumes and concentrations, and with minimal sample preparation. Scientists involved in the development of gene therapies and AAV-based therapies will now be able to improve productivity and accelerate workflows through more frequent in-house testing, making R&D and development of much more efficient processes.

First commercialized by Refeyn, mass photometry is a unique bioanalytical technology that measures molecular mass at the single-particle level by quantifying the scattering of light from biomolecules in solution. The technique offers significant advantages for AAV analysis over alternative methods, such as transmission electron microscopy (TEM), analytical ultracentrifugation (AUC), and ELISA/qPCR. These methods often require more investment, space, sample and expertise, or can only provide limited information compared to mass photometry. Samux^deputyis a serotype-independent instrument that provides comparable empty-to-full AAV capsid ratio analysis faster, more cost-effectively, and with significantly fewer samples than current methods.

Designed to be easy to use with only basic training, the Samux^deputy mass photometer represents a significant advance in AAV analysis. The instrument has a mass range suitable for AAV analysis and provides accurate results in less than five minutes, from sample loading to final result. Combined with low operating costs and a small footprint, the Samux^deputy enables routine quantification of empty/full AAV capsid ratios, even in small labs, to set a new standard in AAV characterization.

“We are delighted to announce the launch of our Samux^deputy mass photometer for fast, accurate and accessible AAV analysis,” said Refeyn CEO Anthony Fernandez. “Mass photometry offers an opportunity to overcome the analytical bottleneck in the field of gene therapy for AAV-based therapeutics and we wanted to develop an instrument that would allow a real gain in efficiency. Samux^deputy delivers accurate results on the bench while reducing cost and setup time. This will allow researchers to focus on what they do best and make AAV analysis another part of their daily workflows. We look forward to working with the bioscience research community to continue to provide innovative instruments that will simplify the characterization of biomolecules. »